(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Raw oysters linked to ongoing salmonella outbreak infecting 64 across 22 states: CDC- Instructions to Warmly greet Certainty and Appeal
- Brazil Passes Law to Use Seized Bitcoin, Crypto to Fund Public Security Measures
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
- Instructions to Floss Appropriately and Forestall Gum Sickness
- Vote in favor of Your Number one BWM Vehicles
- Vote in favor of the bloom plan that adds a bit of excellence to your life!
